Granted Patent
B2
US 12,358,866 · App. 18/433,950 · Granted Jul 15, 2025
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Assignee:
REATA PHARMACEUTICALS HOLDINGS, LLC
C07C255/47C07C271/24C07C275/26C07C275/34C07C311/07C07C311/09C07C311/10C07D209/56C07D211/44C07D231/12C07D261/08C07D261/20C07D295/195C07D295/215C07D307/20C07D333/34C07D487/08C07J63/008C07C2603/52
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
Claims (45)
1. A method of suppressing the demyelination of neurons in a patient's brain or spinal cord, comprising administering to the patient an effective amount of a compound of the formula:
wherein:
R 1 and R 2 are independently:
hydrogen; or
alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heteroaralkyl (C≤12) , acyl (C≤12) , alkylsulphonyl, alkenylsulphonyl (C≤12) , alkynylsulphonyl (C≤12) , arylsulphonyl (C≤12) , aralkylsulphonyl (C≤12) , heteroarylsulphonyl (C≤12) , heteroaralkyl-sulphonyl (C≤12) , or a substituted version of any of these groups;
or pharmaceutically acceptable salts, tautomers, or optical isomers thereof.
2. The method of claim 1 , wherein the bond joining carbon 9 and carbon 11 of the compound is a double bond.
3. The method of claim 1 , wherein the bond joining carbon 9 and carbon 11 of the compound is a single bond.
4. The method of claim 1 , wherein the patient has a neurodegenerative disease.
5. The method of claim 4 , wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, multiple sclerosis (MS), Huntington's disease and amyotrophic lateral sclerosis.
6. The method of claim 1 , wherein the compound is administered systemically.
7. The method of claim 6 , wherein the compound is administered intravenously, intra-arterially, intramuscularly, intraperitoneally, subcutaneously or orally.
8. The method of claim 1 , wherein the effective amount is 0.1-1000 mg/kg.
9. The method of claim 8 , wherein the effective amount is administered in a single dose per day.
10. The method of claim 8 , wherein the effective amount is administered in two or more doses per day.
11. A method of suppressing neuronal apoptosis in a patient's brain or spinal cord, comprising administering to the patient an effective amount of a compound of the formula:
wherein:
Rand R 2 are independently:
hydrogen; or
alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heteroaralkyl (C≤12) , acyl (C≤12) , alkylsulphonyl, alkenylsulphonyl (C≤12) , alkynylsulphonyl (C≤12) , arylsulphonyl (C≤12) , aralkylsulphonyl (C≤12) , heteroarylsulphonyl (C≤12) , heteroaralkyl-sulphonyl (C≤12) , or a substituted version of any of these groups;
or pharmaceutically acceptable salts, tautomers, or optical isomers thereof.
12. The method of claim 11 , wherein the bond joining carbon 9 and carbon 11 of the compound is a double bond.
13. The method of claim 11 , wherein the bond joining carbon 9 and carbon 11 of the compound is a single bond.
14. The method of claim 11 , wherein the patient has a neurodegenerative disease.
15. The method of claim 14 , wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, multiple sclerosis (MS), Huntington's disease and amyotrophic lateral sclerosis.
16. The method of claim 11 , wherein the compound is administered systemically.
17. The method of claim 16 , wherein the compound is administered intravenously, intra-arterially, intramuscularly, intraperitoneally, subcutaneously or orally.
18. The method of claim 11 , wherein the effective amount is 0.1-1000 mg/kg.
19. The method of claim 18 , wherein the effective amount is administered in a single dose per day.
20. The method of claim 18 , wherein the effective amount is administered in two or more doses per day.
21. A method of stimulating the remyelination of neuron axons in a patient's brain or spinal cord, comprising administering to the patient an effective amount of a compound of the formula:
wherein:
R 1 and R 2 are independently:
hydrogen; or
alkyl (C≤12) , alkenyl (C≤12) , alkynyl (C≤12) , aryl (C≤12) , aralkyl (C≤12) , heteroaryl (C≤12) , heteroaralkyl (C≤12) , acyl (C≤12) , alkylsulphonyl, alkenylsulphonyl (C≤12) , alkynylsulphonyl (C≤12) , arylsulphonyl (C≤12) , aralkylsulphonyl (C≤12) , heteroarylsulphonyl (C≤12) , heteroaralkyl-sulphonyl (C≤12) , or a substituted version of any of these groups;
or pharmaceutically acceptable salts, tautomers, or optical isomers thereof.
22. The method of claim 21 , wherein the bond joining carbon 9 and carbon 11 of the compound is a double bond.
23. The method of claim 21 , wherein the bond joining carbon 9 and carbon 11 of the compound is a single bond.
24. The method of claim 21 , wherein the patient has a neurodegenerative disease.
25. The method of claim 24 , wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, multiple sclerosis (MS), Huntington's disease and amyotrophic lateral sclerosis.
26. The method of claim 21 , wherein the compound is administered systemically.
27. The method of claim 26 , wherein the compound is administered intravenously, intra-arterially, intramuscularly, intraperitoneally, subcutaneously or orally.
28. The method of claim 21 , wherein the effective amount is 0.1-1000 mg/kg.
29. The method of claim 28 , wherein the effective amount is administered in a single dose per day.
30. The method of claim 28 , wherein the effective amount is administered in two or more doses per day.
Continuity (11)
Provisional Application
61111269
· Nov 4, 2008
Provisional Application
61046342
· Apr 18, 2008
References Cited (400)
US 4395423A
· Neumann
· 1983
[cited by applicant]
US 4808614A
· Hertel
· 1989
[cited by applicant]
US 5013649A
· Wang et al.
· 1991
[cited by applicant]
US 5064823A
· Lee et al.
· 1991
[cited by applicant]
US 5401838A
· Chou
· 1995
[cited by applicant]
US 5426183A
· Kjell
· 1995
[cited by applicant]
US 5464826A
· Grindey et al.
· 1995
[cited by applicant]
US 5521294A
· Wildfeuer
· 1996
[cited by applicant]
US 5597124A
· Kessel et al.
· 1997
[cited by applicant]
US 5603958A
· Morein et al.
· 1997
[cited by applicant]
US 5606048A
· Chou et al.
· 1997
[cited by applicant]
US 5972703A
· Long et al.
· 1999
[cited by applicant]
US 6025395A
· Breitner et al.
· 2000
[cited by applicant]
US 6303569B1
· Greenwald et al.
· 2001
[cited by applicant]
US 6326507B1
· Gribble et al.
· 2001
[cited by applicant]
US 6369101B1
· Carlson
· 2002
[cited by applicant]
US 6485756B1
· Aust et al.
· 2002
[cited by applicant]
US 6552075B2
· Gribble et al.
· 2003
[cited by applicant]
US 6642217B2
· Krasutsky et al.
· 2003
[cited by applicant]
US 6649654B1
· Karin et al.
· 2003
[cited by applicant]
US 6951847B2
· Gibson et al.
· 2005
[cited by applicant]
US 6974801B2
· Honda et al.
· 2005
[cited by applicant]
US 7053119B2
· Karin et al.
· 2006
[cited by applicant]
US 7144875B2
· Gibson et al.
· 2006
[cited by applicant]
US 7176237B2
· Honda et al.
· 2007
[cited by applicant]
US 7265096B2
· Gallop et al.
· 2007
[cited by applicant]
US 7288568B2
· Gribble et al.
· 2007
[cited by applicant]
US 7399606B2
· Karin et al.
· 2008
[cited by applicant]
US 7410958B2
· Krasutsky et al.
· 2008
[cited by applicant]
US 7435755B2
· Konopleva et al.
· 2008
[cited by applicant]
US 7678830B2
· Honda et al.
· 2010
[cited by applicant]
US 7714012B2
· Honda et al.
· 2010
[cited by applicant]
US 7795305B2
· Konopleva et al.
· 2010
[cited by applicant]
US 7863327B2
· Gribble et al.
· 2011
[cited by applicant]
US 7915402B2
· Anderson et al.
· 2011
[cited by applicant]
US 7943778B2
· Jiang et al.
· 2011
[cited by applicant]
US 8034955B2
· Gribble et al.
· 2011
[cited by applicant]
US 8067394B2
· Honda et al.
· 2011
[cited by applicant]
US 8067465B2
· Honda et al.
· 2011
[cited by applicant]
US 8071632B2
· Jiang et al.
· 2011
[cited by applicant]
US 8088824B2
· Walling et al.
· 2012
[cited by applicant]
US 8124656B2
· Anderson et al.
· 2012
[cited by applicant]
US 8124799B2
· Anderson et al.
· 2012
[cited by applicant]
US 8129429B2
· Sporn et al.
· 2012
[cited by applicant]
US 8258329B2
· Anderson et al.
· 2012
[cited by applicant]
US 8299046B2
· Sporn et al.
· 2012
[cited by applicant]
US 8309601B2
· Walling et al.
· 2012
[cited by applicant]
US 8314137B2
· Honda et al.
· 2012
[cited by applicant]
US 8338618B2
· Jiang et al.
· 2012
[cited by applicant]
US 8394967B2
· Jiang et al.
· 2013
[cited by applicant]
US 8440820B2
· Anderson et al.
· 2013
[cited by applicant]
US 8440854B2
· Anderson et al.
· 2013
[cited by applicant]
US 8455544B2
· Sporn et al.
· 2013
[cited by applicant]
US 8513436B2
· Anderson et al.
· 2013
[cited by applicant]
US 8586775B2
· Gribble et al.
· 2013
[cited by applicant]
US 8747901B2
· Zhang et al.
· 2014
[cited by applicant]
US RE45288E
· Anderson et al.
· 2014
[cited by applicant]
US 8921419B2
· Gribble et al.
· 2014
[cited by applicant]
US RE45325E
· Anderson et al.
· 2015
[cited by applicant]
US 8993640B2
· Anderson et al.
· 2015
[cited by applicant]
US 9000188B2
· Honda et al.
· 2015
[cited by applicant]
US 9090574B2
· Anderson et al.
· 2015
[cited by applicant]
US 9102681B2
· Anderson et al.
· 2015
[cited by applicant]
US 9174941B2
· Anderson et al.
· 2015
[cited by applicant]
US 9233998B2
· Anderson et al.
· 2016
[cited by applicant]
US 9249089B2
· Jiang et al.
· 2016
[cited by applicant]
US 9278912B2
· Jiang et al.
· 2016
[cited by applicant]
US 9278913B2
· Gribble et al.
· 2016
[cited by applicant]
US 9290536B2
· Anderson et al.
· 2016
[cited by applicant]
US 9464082B2
· Donner et al.
· 2016
[cited by applicant]
US 9512094B2
· Jiang et al.
· 2016
[cited by applicant]
US 9556222B2
· Anderson et al.
· 2017
[cited by applicant]
US 9593074B2
· Bender et al.
· 2017
[cited by applicant]
US 9670147B2
· Anderson et al.
· 2017
[cited by applicant]
US 9701709B2
· Anderson et al.
· 2017
[cited by applicant]
US 9757359B2
· Sporn et al.
· 2017
[cited by applicant]
US 9796668B2
· Anderson et al.
· 2017
[cited by applicant]
US 9856286B2
· Sheikh et al.
· 2018
[cited by applicant]
US 9884809B2
· Anderson et al.
· 2018
[cited by applicant]
US 9889143B2
· Jiang et al.
· 2018
[cited by applicant]
US 20020042535A1
· Gribble et al.
· 2002
[cited by applicant]
US 20040097436A1
· Krasutsky et al.
· 2004
[cited by applicant]
US 20050208151A1
· Hurez et al.
· 2005
[cited by applicant]
US 20050276836A1
· Wilson et al.
· 2005
[cited by applicant]
US 20060258752A1
· Vander Jagt
· 2006
[cited by applicant]
US 20070232577A1
· Xu et al.
· 2007
[cited by applicant]
US 20070244081A1
· Krasutsky et al.
· 2007
[cited by applicant]
US 20070249561A1
· Taylor
· 2007
[cited by applicant]
US 20070259839A1
· Krasutsky et al.
· 2007
[cited by applicant]
US 20070259842A1
· Krasutsky et al.
· 2007
[cited by applicant]
US 20080234368A9
· Gribble et al.
· 2008
[cited by applicant]
US 20080254055A1
· Oblong et al.
· 2008
[cited by applicant]
US 20090048205A1
· Meyer et al.
· 2009
[cited by applicant]
US 20090060873A1
· Sporn et al.
· 2009
[cited by applicant]
US 20110250300A1
· Biswal et al.
· 2011
[cited by applicant]
US 20140073700A1
· Wagner et al.
· 2014
[cited by applicant]
US 20140088163A1
· Jiang et al.
· 2014
[cited by applicant]
US 20150080465A1
· Chin et al.
· 2015
[cited by applicant]
US 20180094020A1
· Sheikh et al.
· 2018
[cited by applicant]
US 20230111914A1
· Bender et al.
· 2023
[cited by applicant]
CN 101117348A
· 2006
[cited by applicant]
CN 102070697A
· 2010
[cited by applicant]
CN 102887936
· 2012
[cited by applicant]
CN 103788166
· 2012
[cited by applicant]
DE 102005041613
· 2007
[cited by applicant]
EP 0272891A2
· 1988
[cited by applicant]
EP 0329348B1
· 1995
[cited by applicant]
EP 0376518B1
· 1995
[cited by applicant]
EP 0576230B1
· 1996
[cited by applicant]
EP 0577303B1
· 1997
[cited by applicant]
EP 0712860B1
· 2001
[cited by applicant]
JP 55055153
· 1980
[cited by applicant]
JP 2001240573
· 2001
[cited by applicant]
JP 2005314381
· 2005
[cited by applicant]
JP 2006347952
· 2006
[cited by applicant]
JP 2008110962
· 2008
[cited by applicant]
JP 2008247898
· 2008
[cited by applicant]
WO WO1991015498
· 1991
[cited by applicant]
WO WO1998000173
· 1998
[cited by applicant]
WO WO1998032762
· 1998
[cited by applicant]
WO WO1999033483
· 1999
[cited by applicant]
WO WO1999065478
· 1999
[cited by applicant]
WO WO2001001135
· 2001
[cited by applicant]
WO WO2002003996
· 2002
[cited by applicant]
WO WO2002026761
· 2002
[cited by applicant]
WO WO2002026762
· 2002
[cited by applicant]
WO WO2002032410
· 2002
[cited by applicant]
WO WO2002047611
· 2002
[cited by applicant]
WO WO2002092768
· 2002
[cited by applicant]
WO WO2003043631
· 2003
[cited by applicant]
WO WO2003059339
· 2003
[cited by applicant]
WO WO2003062260
· 2003
[cited by applicant]
WO WO2004064723
· 2004
[cited by applicant]
WO WO2004089357
· 2004
[cited by applicant]
WO WO2005042002
· 2005
[cited by applicant]
WO WO2005046732
· 2005
[cited by applicant]
WO WO2005063295
· 2005
[cited by applicant]
WO WO2006029221
· 2006
[cited by applicant]
WO WO2007005879
· 2007
[cited by applicant]
WO WO2007069895
· 2007
[cited by applicant]
WO WO2007112043
· 2007
[cited by applicant]
WO WO2007127791
· 2007
[cited by applicant]
WO WO2008000068
· 2008
[cited by applicant]
WO WO2008000070
· 2008
[cited by applicant]
WO WO2008016095
· 2008
[cited by applicant]
WO WO2008063318
· 2008
[cited by applicant]
WO WO2008064132
· 2008
[cited by applicant]
WO WO2008064133
· 2008
[cited by applicant]
WO WO2008097596
· 2008
[cited by applicant]
WO WO2008111497
· 2008
[cited by applicant]
WO WO2008136838
· 2008
[cited by applicant]
WO WO2009023232
· 2009
[cited by applicant]
WO WO2009023845
· 2009
[cited by applicant]
WO WO2009058849
· 2009
[cited by applicant]
WO WO2009089545
· 2009
[cited by applicant]
WO WO2009129545
· 2009
[cited by applicant]
WO WO2009129546
· 2009
[cited by applicant]
WO WO2009129548
· 2009
[cited by applicant]
WO WO2009146216
· 2009
[cited by applicant]
WO WO2009146218
· 2009
[cited by applicant]
WO WO2010011782
· 2010
[cited by applicant]
WO WO2010053817
· 2010
[cited by applicant]
WO WO2010093944
· 2010
[cited by applicant]
WO WO2010127029
· 2010
[cited by applicant]
WO WO2011130302
· 2011
[cited by applicant]
WO WO2011140078
· 2011
[cited by applicant]
WO WO2012083306
· 2012
[cited by applicant]
WO WO2012106190
· 2012
[cited by applicant]
WO WO2012125488
· 2012
[cited by applicant]
WO WO2012154554
· 2012
[cited by applicant]
WO WO2013163344
· 2013
[cited by applicant]
WO WO2013169553
· 2013
[cited by applicant]
WO WO2013169740
· 2013
[cited by applicant]
WO WO2013188818
· 2013
[cited by applicant]
WO WO2014040052
· 2014
[cited by applicant]
WO WO2014040056
· 2014
[cited by applicant]
WO WO2014040060
· 2014
[cited by applicant]
WO WO2014040073
· 2014
[cited by applicant]
WO WO2014048033
· 2014
[cited by applicant]
WO WO2014176415
· 2014
[cited by applicant]
WO WO2015027206
· 2015
[cited by applicant]
WO WO2015112792
· 2015
[cited by applicant]
WO WO2016130927
· 2016
[cited by applicant]
WO WO2017053868
· 2017
[cited by applicant]
WO WO2018089539
· 2018
[cited by applicant]
WO WO2018111315
· 2018
[cited by applicant]
WO WO2000073253
· 2020
[cited by applicant]
“CDDO in treating patients with metastatic or unresectable solid tumors or lymphoma,” www.clinicaltrials.gov/ct2/show/NCT00352040?term=CDDO&rank=1, Dec. 14, 2008.
[cited by applicant]
“FDA mulls drug to slow late-stage Alzheimer's,” www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html, Retrieved on Sep. 23, 2003.
[cited by applicant]
“Phase IIa trail to determine the effects of bardoxolone methyl on renal function in patients with diabetic nephropathy,” www.clinicaltrials.gov/ct2/show/NCT00664027?term=rta&rank=10, Dec. 14, 2008.
[cited by applicant]
“RTA 402 in advanced solid tumors or lymphoid malignancies,” www.clinicaltrials.gov/ct2/show/NCT00508807?term=rta&rank=2&show_desc=Y, Dec. 14, 2008.
[cited by applicant]
“Study to assess the safety, tolerability, and pharmacodynamics of RTA 402 in patients with hepatic dysfunction,” www.clinicaltrials.gov/ct2/show/NCT00550849?term=rta&rank=4, Dec. 14, 2008.
[cited by applicant]
Abraham and Kappas, “Heme oxygenase and the cardiovascular-renal system,”
[cited by applicant]
Agarwal and Mehta, “Possible involvement of Bcl-2 pathway in retinoid X receptor α-induced apoptosis of HL-60 cells,”
[cited by applicant]
Ahmad et al., “Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179”,
[cited by applicant]
Ahmad et al., “Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-→ signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3,”
[cited by applicant]
Akiyama, et al., “Cell mediators of inflammation in the Alzheimer disease brain,”
[cited by applicant]
Akrivakis et al., “Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study,”
[cited by applicant]
Alabran, et al., “Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO,”
[cited by applicant]
Al-Alami et al., “Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukemia cells,”
[cited by applicant]
Albini and Sporn, “Opinion: the tumour microenvironment as a target for chemoprevention,”
[cited by applicant]
Alexander et al., “Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside,”
[cited by applicant]
Ambs et al., “p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells,”
[cited by applicant]
Ames, et al., “The Triterpenoid CDDO-Me Promotes Hematopoietic Progenitor Expansion and Myelopoiesis in Mice,”
[cited by applicant]
Amstutz et al., “Die position 5 im oxotremorin-gerust: eine zentrale stelle fur die steuerung der aktivitat am muscarinischen rezeptor,”
[cited by applicant]
Andreeff et al., “Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and cationic acid,”
[cited by applicant]
Andreeff et al., “PPARγ nuclear receptor as a novel molecular target in leukemias,”
[cited by applicant]
Andreeff, “Acute myeloid leukemia,”
[cited by applicant]
Andrew E. Place, “Pre-clincial evaluation of the novel synthetic triterpenoid CDDO-Imidazolide,” Thesis, Dartmouth College, May 5, 2004.
[cited by applicant]
Araujo et al., “Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse,”
[cited by applicant]
Ardestani et al., “Effects of dexamethasone and betamethasone as COX-2 gene expression inhibitors on rigidity in a rat model of Parkinson's disease,”
[cited by applicant]
Ariga et al., “Role of sphingolipid-mediated cell death in neurodegenerative diseases,”
[cited by applicant]
Bach, “Heme oxygenase-1 and transplantation tolerance,”
[cited by applicant]
Baeuerle, “NF-κB: ten years after,”
[cited by applicant]
Bagasra et al., “Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis,”
[cited by applicant]
Bai, et al., “Modified compounds from ursolic acid and their antitumor activities,”
[cited by applicant]
Baker et al., “2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase,”
[cited by applicant]
Baldwin, Jr., “The NF-κB and IκB proteins: new discoveries and insights,”
[cited by applicant]
Balkwill et al., “Smoldering and polarized inflammation in the initiation and promotion of malignant disease,”
[cited by applicant]
Ballesta-Acosta, et al., “A new 24-nor-oleanane triterpenoid from Salvia carduacea,”
[cited by applicant]
Bargou et al., “Constitutive nuclear factor κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells,”
[cited by applicant]
Barkett and Gilmore, “Control of apoptosis by Rel/NF-κB transcription factors,”
[cited by applicant]
Barnes and Karin, “Nuclear factor-κB—a pivotal transcription factor in chronic inflammation diseases,”
[cited by applicant]
Barton, et al., “The synthesis of β-amyrin,”
[cited by applicant]
Beal, “Mitochondria, free radicals, and neurodegeneration,”
[cited by applicant]
Begum et al., “Synthesis of 2β-hydroxyursolic acid and other ursane analogs from ursonic acid,” Australian Journal of Chemistry, 46(7):1067-1071, 1993.
[cited by applicant]
Beran et al., “Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia,”
[cited by applicant]
Bliard et al., “Glycosylation of acids under phase transfer conditions. Partial synthesis of saponins,”
[cited by applicant]
Bogdan and Ding, “Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages,”
[cited by applicant]
Bogdan et al., “Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10,”
[cited by applicant]
Bollag and Holdener, “Retinoids in cancer prevention and therapy,”
[cited by applicant]
Boolbol et al., “Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis,”
[cited by applicant]
Bore et al., “The anti-inflammatory triterpenoid methyl 2-cyano-3, 12-dioxoolean 1,9(11)-dien-28-oate methanol solvate hydrate,”
[cited by applicant]
Bowden et al., “Constituents of the fruit of pseudopanax arboreum (Araliaceae),”
[cited by applicant]
Brookes et al., “The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability trans…
[cited by applicant]
Bruder and Caplan, “A monoclonal antibody against the surface of osteoblasts recognizes alkaline phosphatase isoenzymes in bone, liver, kidney, and intestine,”
[cited by applicant]
Bruder and Caplan, “First bone formation and the dissection of an osteogenic lineage in the embryonic chick tibia is revealed by monoclonal antibodies against osteoblasts,”
[cited by applicant]
Bruder et al., “Terminal osteogenic cell differentiation in culture requires beta-glycerol phosphate,”
[cited by applicant]
Bruland et al., “Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen,”
[cited by applicant]
Buchanan and Halsall, “The conversion of turraeanthin and turraeanthin A into simple melaiacins by a route involving an oxidative rearrangement of probable biogenetic importance,”
[cited by applicant]
Buzoni-Gatel et al., “Intraepithelial lymphocytes traffic to the intestine and enhance resistance to Toxoplasma gondii oral infection,”
[cited by applicant]
Buzoni-Gatel et al., “Murine ileitis after intracellular parasite infection is controlled by TGF-beta-producing intraepithelial lymphocytes,”
[cited by applicant]
Cai and Vasella, “A new protecting group for alkynes: orthogonally protected dialkynes,”
[cited by applicant]
Campbell et al., “Endocyclic α,β-unsaturated ketones. VI. Ultraviolet and infrared absorption spectra and resonance stabalization,”
[cited by applicant]
Carter et al., “Expression of survivin, a member of the inhibitor of apoptosis (IAP) family of caspase inhibitors is expressed in AML and regulated by cytokines and ATRA,”
[cited by applicant]
Cassady and Suffness, In
[cited by applicant]
Castaigne et al., “All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia,”
[cited by applicant]
Cerwenka and Swain, “TGF-β1: immunosuppressant and viability factor for T lymphocytes,”
[cited by applicant]
Chadalapaka, et al., “Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives,”
[cited by applicant]
Chattopadhyay et al., “Studies on autoxidation: Part IV. Synthesis of isomeric 2,3-diols of olean-12-en-28-oate and isohopane (moretane),”
[cited by applicant]
Chauhan et al., “The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance,”
[cited by applicant]
Chen et al., “Chondrogenesis in chick limb bud mesodermal cells: reciprocal modulation by activin and inhibin,”
[cited by applicant]
Chen et al., “Stimulation of chondrogenesis in limb bud mesoderm cells by recombinant human bone morphogenetic protein 2B (BMP-2B) and modulation by transforming growth factor beta 1 and beta 2,”
[cited by applicant]
Cheng et al., “Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone,”
[cited by applicant]
Chintharlapalli et al., “2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor γ-dependent and-independent pathways,”
[cited by applicant]
Chintharlapalli et al., “2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor γ in colon and pancreatic cancer cells,”
[cited by applicant]
Chintharlapalli et al., “Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ agonists in colon cancer cells,”
[cited by applicant]
Cho et al., “The transcription factor NRF2 protects against pulmonary fibrosis,”
[cited by applicant]
Chou et al., “Stereospecific Synthesis of 2-Deoxy-2, 2-difluororibonolactone and its Use in the Preparation of 2′-Deoxy-2′, 2′-difluoro-B—D-ribofuranosyl Pyrimidine Nucleosides: The Key Role of Selective Crystallization…
[cited by applicant]
Chung and Wasicak, “Synthesis of chiral ∀-acetylenic cyclic amines from ∀-amino acids: Apps to differentially constrained oxotremorine analogues as muscarinic agents,”
[cited by applicant]
Cianchi et al., “Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer,”
[cited by applicant]
Clinicaltrials.gov Study Record, NCT 00352040, “CDDO in treating patients with metastatic or unresectable solid tumors or lymphoma conditions: lymphoma; small intestine cancer; unspecified adult solid tumor, protocol sp…
[cited by applicant]
C76. Clinicaltrials.gov Study Record, NCT 00508807, “RTA 402 in advanced solid tumors or lymphoid malignancies conditions: lymphoid malignancies; solid tumors,” update of Aug. 27, 2008.
[cited by applicant]
Clinicaltrials.gov Study Record, NCT 00529113, “Study with gemcitabine and RTA 402 for patients with unresectable pancreatic cancer,” update of Jun. 12, 2008.
[cited by applicant]
Clinicaltrials.gov Study Record, NCT 00529438, “RTA 402 in patients with advanced solid tumors or lymphoid malignancies conditions: advanced solid tumors; lymphoid malignancies,” update of Dec. 21, 2008.
[cited by applicant]
Clinicaltrials.gov Study Record, NCT 00550849, “Study to assess the safety, tolerability, and pharmacodynamics of RTA 402 in patients with hepatic dysfunction condition: liver disease,” update of Nov. 6, 2007.
[cited by applicant]
Clinicaltrials.gov Study Record, NCT 00664027, “Phase IIa trial to determine the effects of bardoxolone methyl on renal function in patients with diabetic nephropathy condition: diabetic nephropathy,” update of Feb. 18,…
[cited by applicant]
Clinicaltrials.gov Study Record, NCT 00811889, “Trial to determine the effects of bardoxolone methyl on eGFR in patients with type 2 diabetes and chronic kidney disease conditions: chronic kidney disease; type 2 diabete…
[cited by applicant]
Clinton et al., “Steroidal[3,2-c]pyrazoles. II. Androstanes, 19-norandrostanes and their unsaturated analogs,”
[cited by applicant]
Cohen, et al., “A general method for removal of a 4-methyl group from triterpenoids. Synthesis of 4β-demethylgylycyrrhetinic acid,”
[cited by applicant]
Connolly, et al., “Grandiofolione: a novel tetranortriterpenoid,”
[cited by applicant]
Corey and Ruden, “Stereoselective methods for the synthesis of terminal cis AND trans enyne units,”
[cited by applicant]
Couch et al., “2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid disrupts microtubule polymerization: a possible mechanism contributing to apoptosis,”
[cited by applicant]
Couch et al., “Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action,”
[cited by applicant]
Coyle and Puttfarcken, “Oxidative stress, glutamate, and neurodegenerative disorders,”
[cited by applicant]
Cripe, “Adult Acute Leukemia,”
[cited by applicant]
Cuadrado, “NRF2 in neurodegenerative diseases”,
[cited by applicant]
Cui, “A material science perspective of pharmaceutical solids,”
[cited by applicant]
Damasio, “Alzheimer's Disease and Related Dementias,” Cecil Textbook of Medicine, 20th edition, 2:1992-1996, 1996.
[cited by applicant]
Damsté, et al., “A sedimentary tetrahydrophenanthrene derivative of tetrahymanol,” Tetrahedron Letters, 40(20):3949-3952, 1999.
[cited by applicant]
Das and Mahato, “Triterpenoid sapogenols from the leaves of Careya Arborea: Structure of careyagenolide,”
[cited by applicant]
Dean et al., “Halogenolysis of methyl glycyrrhetate with lithium iodidedimethylformamide,”
[cited by applicant]
Deeb, et al., “CDDO-Me Induces Apoptosis and Inhibits Akt, mTOR, and NF-κB Signaling Proteins in Prostate Cancer Cells,”
[cited by applicant]
Deeb, et al., “CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-κB and NF-κB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells,”
[cited by applicant]
Deng and Snyder, “Preparation of a 24-Nor-1,4-dien-3-one triterpene derivative from betulin: a new route to 24-nortriterpene analogues,”
[cited by applicant]
Devi et al., “Constituents of black dammar resin and some transformation products of α-and β-amyrins,”
[cited by applicant]
Dezube et al., “Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies,”
[cited by applicant]
Di Stefano et al., “Inhibition of [3H]thymidine incorporation into DNA of rat regenerating liver by 2′,2′-difluorodeoxycytidine coupled to lactosaminated poly-L-lysine,”
[cited by applicant]
Ding et al., “Macrophage deactivating factor and transforming growth factors-β1 β2 and β3, inhibit induction of macrophage nitrogen oxide synthesis by IFNγ
[cited by applicant]
Dinkova-Kostova et al., “Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress,”
[cited by applicant]
Dinkova-Kostova, et al., “Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants,”
[cited by applicant]
Dirsch, et al., “The triterpenoid quinomethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages,”
[cited by applicant]
Drach et al., “Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid,”
[cited by applicant]
Dracinsky, et al., “Preparation and Conformational Study of 19β,28-Epoxy-18α-olean-5-ene derivatives,”
[cited by applicant]
Dragnev et al., “Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy,”
[cited by applicant]
Dragnev et al., “The retinoids and cancer prevention mechanisms,”
[cited by applicant]
Drefahl and Huneck, “Nor-olea-12-enol-17-amin und Olea-12-enol-28-amin,”
[cited by applicant]
Duan et al., “Immunosuppressive terpenoids from extracts of tripterygium wilfordii,”
[cited by applicant]
Duan, et al., “CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells,”
[cited by applicant]
Duan, et al., “Di- and triterpenoids from Triptergium hypoglaucum,” Phytochemistry, 46(3):535-543, 1997.
[cited by applicant]
Dubois et al., “G
[cited by applicant]
Dubois et al., “Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors,”
[cited by applicant]
Dutcher et al., “Pentacyclic triterpene synthesis. 5. Synthesis of optically pure ring AB precursors,”
[cited by applicant]
Ekmekcioglu et al., “Tumor iNOS predicts poor survival for stage III melanoma patients,”
[cited by applicant]
Elgamal et al., “Glycyrrhetic acid derivatives with modified ring A,”
[cited by applicant]
Elgamal et al., “The C-2, C-3-glycol derivatives of glycyrrhetic acid,”
[cited by applicant]
Ellies et al., “Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase,”
[cited by applicant]
Elliot et al., “The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes,”
[cited by applicant]
Elsawa et al., “Preferential Inhibition of Malignant Cell Growth by CDDO in Waldenstrom Macroglobulinemia,”
[cited by applicant]
Elsawa, et al., “CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenstroem macroglobulinemia,”
[cited by applicant]
Elstner et al., “Ligands for peroxisome proliferator-activated receptor y and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,”
[cited by applicant]
Embleton et al., “Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line,”
[cited by applicant]
Endová et al., “Preparation of 2,3-secodiacids of the lupane series,”
[cited by applicant]
Engel et al., “Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells,”
[cited by applicant]
English summary of Office Communication issued in Colombian Patent Application No. 10.143.959, dated Nov. 23, 2012.
[cited by applicant]
English translation of Office Communication issued in corresponding Chinese Patent Application 2013012400658910, dated Jan. 29, 2013.
[cited by applicant]
Estey et al., “Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia,”
[cited by applicant]
Estey et al., “Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid + granulocyte-colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and …
[cited by applicant]
Evers et al., “Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action,”
[cited by applicant]
Favaloro, Jr. et al., “Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages,”
[cited by applicant]
Finkbeiner and Stiles, “Chelation as a driving force in organic reactions. IV. Synthesis of a ∀-nitro acids by control of the carboxylastion-decarboxylation equilibrum,”
[cited by applicant]
Finlay, et al., “Novel A-ring cleaved analogs of oleanolic and ursolic acids which affect growth regulation in NRP.152 prostate cells,”
[cited by applicant]
Finlay, et al., “The Effect of A and C Ring Modification of Oleanolic and Ursolic Acid on the Inhibition of Nitric Oxide Formation in Mouse Macrophages,” 213th American Chemical Society National Meeting, Abstract:084, 1…
[cited by applicant]
Gandhi et al., “Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia,”
[cited by applicant]
Ganguly et al., “Oxidation of ring in a lupeol,”
[cited by applicant]
Ganguly, et al., “Chemical constituents of Glochidion hohenackeri,”
[cited by applicant]